148 related articles for article (PubMed ID: 17510265)
1. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Valéria Dos Santos K; Diniz CG; Coutinho SC; Apolônio ACM; Geralda de Sousa-Gaia L; Nicoli JR; Farias LM; Roque de Carvalho MA
J Med Microbiol; 2007 Jun; 56(Pt 6):798-802. PubMed ID: 17510265
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
3. In vitro selection of ertapenem and piperacillin/tazobactam-resistant strains of Bacteroides fragilis and analysis of their virulence in gnotobiotic mice.
Valéria Dos Santos K; Roque DE Carvalho MA; Amancio Martins W; Coutinho SC; Bahia JL; Lopes DE Andrade JP; Morais Apolonio AC; Cara DC; Galuppo Diniz C; Nicoli JR; DE Macedo Farias L
J Chemother; 2010 Aug; 22(4):259-63. PubMed ID: 20685630
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli.
Santos KVD; Nicoli JR; Martins WA; Coutinho SC; Apolônio ACM; Diniz CG; Carvalho MAR; Farias LM
J Med Microbiol; 2007 Nov; 56(Pt 11):1576-1579. PubMed ID: 17965366
[No Abstract] [Full Text] [Related]
5. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Raveh D; Yinnon AM; Broide E; Rudensky B
Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.
Stearne LE; van Boxtel D; Lemmens N; Goessens WH; Mouton JW; Gyssens IC
Antimicrob Agents Chemother; 2004 May; 48(5):1688-98. PubMed ID: 15105122
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of the in vitro activity of piperacillin/tazobactam.
Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
[TBL] [Abstract][Full Text] [Related]
8. The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.
Goldstein EJ; Citron DM; Tyrrell KL; Leoncio ES; Merriam CV
Anaerobe; 2017 Feb; 43():1-3. PubMed ID: 27713022
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
[TBL] [Abstract][Full Text] [Related]
10. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
11. Killing of Escherichia coli by beta-lactams at different inocula.
Tam VH; Ledesma KR; Chang KT; Wang TY; Quinn JP
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):166-71. PubMed ID: 19304437
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic profiling of commonly prescribed antimicrobial drugs against Escherichia coli isolates from urinary tract.
Cuba GT; Pignatari AC; Patekoski KS; Luchesi LJ; Kiffer CR
Braz J Infect Dis; 2014; 18(5):512-7. PubMed ID: 24731938
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.
Dela Pena AS; Asperger W; Köckerling F; Raz R; Kafka R; Warren B; Shivaprakash M; Vrijens F; Giezek H; DiNubile MJ; Chan CY;
J Gastrointest Surg; 2006 Apr; 10(4):567-74. PubMed ID: 16627223
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.
Schaumann R; Funke M; Janssen E; Rodloff AC
Antimicrob Agents Chemother; 2012 Jun; 56(6):3413-6. PubMed ID: 22430962
[TBL] [Abstract][Full Text] [Related]
15. Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination.
Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F
Chemotherapy; 1990; 36(3):215-21. PubMed ID: 2159865
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
17. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
Venezia RA; Yocum DM; Robbiano EM; Echols RM
Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
[TBL] [Abstract][Full Text] [Related]
19. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
[TBL] [Abstract][Full Text] [Related]
20. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
Namias N; Solomkin JS; Jensen EH; Tomassini JE; Abramson MA
Surg Infect (Larchmt); 2007 Feb; 8(1):15-28. PubMed ID: 17381394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
